Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China’s highest-incidence malignancies.

Clinical Milestone

Regulatory Designations & Prior Evidence

Prior Clinical Performance (FIC/BIC Potential):

• Non-small cell lung cancer (NSCLC): Phase II/registrational trials ongoing
• Small cell lung cancer (SCLC): Registrational-stage development
• Extrapulmonary neuroendocrine carcinoma (NEC): Phase II efficacy signals

Mechanism of Action & Differentiation

Competitive Positioning vs. Standard of Care:

Market Context & Strategic Value

Development Outlook

• Phase II Design: Single-arm or randomized vs. chemo-PD-1 combination; primary endpoint ORR with PFS/OS secondary
• Biomarker Strategy: PD-L1 expression, TMB, and immune infiltrate analysis to identify responder populations
• Combination Potential: Future chemo-PD-1-opamtistomig triplet studies planned
• Regulatory Pathway: China NDA 2027-2028 contingent on Phase II data; U.S. BLA 2028-2029 via ODD/FTD accelerated track

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and competitive positioning for opamtistomig in esophageal squamous cell carcinoma. Actual results may differ due to trial outcomes, competitive dynamics with PD-1 combinations, and manufacturing scale-up challenges.-Fineline Info & Tech